Hims & Hers: The Dominant Health Platform Of The Future

Hims & Hers (HIMS) reported strong Q2 2025 results, with revenue up 73% year-over-year to $544.8 million and adjusted EBITDA reaching $82.2 million, while reaffirming full-year guidance for $2.3-$2.4 billion in revenue. The company is strategically transitioning from a direct-to-consumer telehealth service to a comprehensive, multi-specialty health platform, demonstrated by 2.4 million subscribers and a 30% increase in average monthly subscriber revenue to $74. This evolution includes a diversified weight loss strategy beyond compounded GLP-1s, robust unit economics with over 85% long-term retention, and planned expansion into hormone health, lab testing, and international markets, positioning Hims for continued scalable growth despite some market preoccupation with short-term regulatory dynamics.

Analysis

Hims & Hers is demonstrating a successful transition from a direct-to-consumer telehealth storefront to a scalable, multi-specialty health platform, validated by strong Q2 2025 results. The company reported a 73% year-over-year revenue increase to $544.8 million and reaffirmed full-year guidance of $2.3 to $2.4 billion, signaling confidence despite market noise. The core of its model is strengthening, with subscribers growing 31% to 2.4 million and monthly online average subscriber revenue (ARPU) climbing 30% to $74. These metrics, combined with SaaS-like unit economics featuring over 85% long-term retention and a customer acquisition cost payback of under one year, indicate a highly efficient and durable business model. Strategically, Hims is mitigating regulatory risk in the weight loss segment by diversifying its offerings beyond compounded GLP-1s to include branded injectables and oral medications, thereby capturing a wider patient base and safeguarding revenue streams. Future growth is underpinned by clear expansion initiatives, including the integration of ZAVA Global to penetrate European markets, the upcoming launch of hormone health and lab testing services, and the development of its MedMatch data engine to enhance personalization. While the valuation appears elevated at approximately 4.7x forward EV/Sales and 35x EV/Adjusted EBITDA, it is supported by projected revenue growth of 56-63% for 2025. Key risks to monitor include an FTC investigation into advertising practices and the evolving regulatory landscape for compounded drugs, though the company's sound liquidity, with over $1.1 billion in cash, provides a solid operational buffer.

Key Decisions for Investors

• Investors should evaluate Hims & Hers as a scalable health platform with strong, SaaS-like unit economics, focusing on the 30% ARPU growth and 85%+ long-term retention as primary indicators of its model's viability.
• Monitor the company's strategic pivot in weight loss, as its ability to successfully market a portfolio of compounded, branded, and oral treatments is crucial for de-risking from regulatory changes and sustaining growth.
• Key catalysts to watch for through 2026 include the successful integration and revenue contribution from the ZAVA acquisition in Europe, the U.S. launch of hormone health and lab testing, and the planned market entry into Canada.
• While the valuation appears high, it should be weighed against the company's projected 56-63% revenue growth; however, it is prudent to track headline risk from the FTC investigation and any margin impact from shifts in the product mix.